Fumagillin, a potent angiogenesis inhibitor, induces Kaposi sarcoma-associated herpesvirus replication in primary effusion lymphoma cells

• Published in: Biochemical and biophysical research communications Vol. 463; no. 4; pp. 1267 - 1272
• Main Authors: Kanno, Takayuki, Uehara, Taeko, Osawa, Madori, Fukumoto, Hitomi, Mine, Sohtaro, Ueda, Keiji, Hasegawa, Hideki, Katano, Harutaka
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 07.08.2015
• Subjects: angiogenesis; Angiogenesis inhibitor; Angiogenesis Inhibitors - pharmacology; Cell Division - drug effects; cell growth; Cell Line, Tumor; Cyclohexanes - pharmacology; DNA; Fatty Acids, Unsaturated - pharmacology; Fumagillin; gene expression; growth retardation; Herpesvirus; Herpesvirus 8, Human - genetics; Herpesvirus 8, Human - physiology; Humans; Kaposi sarcoma-associated herpesvirus; Kaposi's sarcoma-associated herpesvirus; lymphoma; Lymphoma - pathology; Lymphoma - virology; neoplasm cells; pathogenesis; Primary effusion lymphoma; quantitative polymerase chain reaction; RNA, Messenger - genetics; sarcoma; Sesquiterpenes - pharmacology; transactivators; Virus Replication - drug effects; Western blotting; Kaposi sarcoma-associated herpesvirus; Primary effusion lymphoma; Angiogenesis inhibitor; Fumagillin

Kaposi sarcoma and primary effusion lymphoma cells are infected with Kaposi sarcoma-associated herpesvirus (KSHV), predominantly in the latent form, and KSHV replication is observed rarely. Angiogenesis plays a crucial role in the pathogenesis of both Kaposi sarcoma and primary effusion lymphoma. In...